The publisher explores Kyowa Kirin’s prescription pharmaceutical performance and outlook over 2019-29.
Snapshot
Model updates (30 October 2020)
Model updates (31 October 2019)
Model updates (14 August 2019)
Snapshot
- Overview - Kyowa Kirin’s late-stage pipeline and exposure to generics mean an increased reliance on new product revenue.
- Key themes - [1] Kyowa Kirin revenue continues to be negatively impacted by branded and generic competition to its portfolio of longer-listed products [2] Kyowa Kirin is combating these sales declines and providing Rx sales growth through its new products such as Orkedia, which is a successor to long-listed product Regpara, and finding opportunities elsewhere with a rituximab biosimilar and growth through overseas activity with Crysvita, Poteligeo, and Nouriast.
Model updates (30 October 2020)
- Nesp forecast adjusted lower due to biosimilar competition
- Crysvita forecast adjusted higher.
Model updates (31 October 2019)
- Biosimilar rituximab forecast adjusted higher due to strong sales growth
- Nouriast forecast adjusted for US launch
- Other Revenue forecast adjusted lower due to the sale of Kyowa Hakko Bio.
Model updates (14 August 2019)
- Crysvita forecast adjusted higher due to strong post-launch results in North America
- Orkedia forecast adjusted higher due to strong reported sales growth
- Poteligeo forecast adjusted higher due to strong US market penetration from successful launch
- Allelock forecast adjusted lower due to increased generic competition
- Abstral forecast adjusted lower due to Brexit issues.
Table of Contents
Company Background
Company Forecast
Company Profile
Clinical Trial Overview
